Log in

ImmuPharma Stock Price, Forecast & Analysis (LON:IMM)

GBX 7.50
-0.93 (-11.03 %)
(As of 11/12/2019 03:32 AM ET)
Today's Range
Now: GBX 7.50
50-Day Range
MA: GBX 9.64
52-Week Range
Now: GBX 7.50
Volume937,733 shs
Average Volume817,845 shs
Market Capitalization£12.55 million
P/E RatioN/A
Dividend YieldN/A
ImmuPharma plc, a pharmaceutical company, develops drug candidates based on peptide therapeutics to treat serious medical conditions. The company's lead product candidate is the Lupuzor, which has completed Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology. Read More…

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales£19,626.00
Cash FlowGBX 1.33 per share
Book ValueGBX 5.30 per share



Market Cap£12.55 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMM News and Ratings via Email

Sign-up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.

ImmuPharma (LON:IMM) Frequently Asked Questions

What is ImmuPharma's stock symbol?

ImmuPharma trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

Has ImmuPharma been receiving favorable news coverage?

Media headlines about IMM stock have been trending very negative recently, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ImmuPharma earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for ImmuPharma.

Who are some of ImmuPharma's key competitors?

What other stocks do shareholders of ImmuPharma own?

Who are ImmuPharma's key executives?

ImmuPharma's management team includes the folowing people:
  • Mr. Dimitri F. Dimitriou, Co-Founder, CEO & Director (Age 57)
  • Dr. D. Robert Henri Zimmer M.D., Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 71)
  • Ms. Tracy Weimar BA, MBA, VP of Operations & Fin. and Company Sec.
  • Dr. Jean-Marie Geiger PharmD, MD, Head of Clinical Devel.

How do I buy shares of ImmuPharma?

Shares of IMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ImmuPharma's stock price today?

One share of IMM stock can currently be purchased for approximately GBX 7.50.

How big of a company is ImmuPharma?

ImmuPharma has a market capitalization of £12.55 million and generates £19,626.00 in revenue each year. ImmuPharma employs 10 workers across the globe.View Additional Information About ImmuPharma.

What is ImmuPharma's official website?

The official website for ImmuPharma is http://www.immupharma.org/.

How can I contact ImmuPharma?

ImmuPharma's mailing address is 50 Broadway, LONDON, SW1H 0BL, United Kingdom. The company can be reached via phone at +44-20-71524080.

MarketBeat Community Rating for ImmuPharma (LON IMM)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  384
MarketBeat's community ratings are surveys of what our community members think about ImmuPharma and other stocks. Vote "Outperform" if you believe IMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Featured Article: 12b-1 Fees

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel